Ro vs Hims (2026): the brand-forward giants after the Novo deal changed one of them
These platforms now sell different things. Ro is the insurance machine: reported cash tiers of $199–349, but its real product is coverage checks and prior-authorization support for branded Zepbound — the highest-value fifteen minutes for anyone whose commercial plan might pay. Hims is the pivot story: after Novo Nordisk's February 2026 lawsuit and the March partnership that ended it, Hims stopped advertising compounded GLP-1s and moved to brand-forward Wegovy offers, making its historical ~$329 compounded figure a museum piece in our dataset. Choose Ro to attack a tirzepatide coverage question; consider Hims for its brand-Wegovy semaglutide lane; choose neither as a cash-pay tirzepatide budget play — that's what the compounded floor and LillyDirect's $299–449 are for.
Ro: buy the machinery, not the medication price
Judged as a cash tirzepatide vendor, Ro's $199–349 reported tiers lose to half the ledger. Judged as what it actually is — the most developed insurance-navigation platform in the category — Ro is frequently the correct first stop even for people who end up buying elsewhere: its coverage check surfaces whether your plan covers Zepbound (including through the sleep-apnea indication most patients don't know to invoke, per the OSA guide), and its PA support does the documentation work that decides approvals. The rational use pattern: run Ro's coverage check before spending any cash anywhere; if coverage lands, a $25–100 copay beats every number on this site; if it fails, take the denial letter — it's appeal fuel — and drop down the cash ladder with clear eyes. Paying Ro's cash tiers only makes sense when its bundled experience is worth the premium to you specifically.
Hims: read the pivot before you subscribe
The Hims of the aggregator tables — compounded semaglutide and tirzepatide at scale — largely stopped existing in March 2026. The sequence: Novo sued over compounded semaglutide marketing in February, dropped the suit on March 9 as the companies partnered, and Hims stopped advertising compounded GLP-1s, moving to brand-forward Wegovy offers (reported tiers in the $149–249 neighborhood for the branded lane). Three consumer implications. Legacy compounded subscribers should get their transition terms in writing — what happens to existing pricing is exactly the kind of detail that varies by cohort. New semaglutide shoppers get a legitimately interesting brand lane: Wegovy with a polished platform, worth comparing against NovoCare's own ~$149 oral and ~$499-class injection self-pay. And tirzepatide shoppers mostly get a redirect — the pivot was a semaglutide deal, so Hims' tirzepatide story is thinner than its brand suggests; our fact sheet flags the historical figures accordingly, with Hers carrying the same house-wide caveat.
The verdict by buyer
Coverage-possible tirzepatide buyer: Ro, immediately, before any cash decision. Brand-semaglutide buyer who values platform polish: Hims' Wegovy lane, cross-shopped against NovoCare direct. Cash tirzepatide buyer: neither — LillyDirect's $299–449 vials for certainty, or the verified compounded ladder for budget, with both giants serving as reminders that the biggest brands in this market monetize navigation and trust, not the lowest price. Which is, incidentally, the market position this site competes with them for — the difference being our navigation ships with statuses, sources, and a dataset you can audit.
Related: NexLife vs Ro · every legal path, priced · who ranks whom
After the pivot: what each platform is actually selling in late 2026
This pairing used to be a compounded-price comparison; the year turned it into a strategy comparison. Hims' arc ran lawsuit-to-partnership: sued by Novo in February, partnered by March, and now brand-forward on Wegovy — meaning its circulating compounded prices (~$329 historical; Hers ~$299 in the April table) describe a discontinued era, and the live question is whether its partnership pricing beats NovoCare direct ($149 oral being the benchmark). Ro's drift rhymes without the litigation: a verified ~$329 compounded figure now sits alongside an increasingly brand-and-insurance-forward posture, with its coverage-check tooling the feature reviewers actually praise. The comparison therefore collapses to a checkout race you can run in ten minutes: open both flows, record what's offered and at what price, and cross-shop each against the direct channels they resell — because in the big-brand tier, the platforms' remaining edge is navigation and bundling, and both verification files now grade exactly that.
Head-to-head FAQ
Is Ro or Hims better for GLP-1s in 2026?
Both are legitimate major platforms that drifted brand-forward this year. Hims runs a Novo partnership centered on Wegovy; Ro's edge is intake rigor and insurance tooling. Cross-shop both live checkouts against NovoCare and LillyDirect direct pricing before choosing either.
Does Hims still offer compounded GLP-1s?
Largely no — after the March 2026 Novo partnership it stopped advertising them and emphasizes brand Wegovy. Old compounded prices in comparison tables are museum pieces.
Is tirzepatide available through Ro or Hims?
Historically both offered compounded tirzepatide (Ro at a verified ~$329); post-pivot availability is fluid and tirzepatide was never part of Hims' Novo deal. Confirm at the live checkout, and compare against LillyDirect's $299–449 brand vials.